{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:42:08Z","timestamp":1793234528973,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T00:00:00Z","timestamp":1338940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            It is known that intravesical botulinum toxin (\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            ) is an effective treatment for overactive bladder, especially in the patients with neurogenic detrusor overactivity. Several studies have shown that diagnostic and health\u2010related quality of life parameters improve after intravesical\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            treatment.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The present study has the merit of reporting a \u2018real\u2010life\u2019 experience in a large teaching hospital in the\n                            <jats:styled-content style=\"fixed-case\">UK N<\/jats:styled-content>\n                            ational\n                            <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>\n                            ealth\n                            <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>\n                            ervice. As opposed to controlled trials, this retrospective study based largely on patient choice, shows that most patients fail to persist with intravesical\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            treatment, mainly due to tolerability issues.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To assess the long\u2010term compliance with repeated injections of intravesical botulinum toxin (\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            ) in a \u2018real\u2010life\u2019 mixed population of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            To identify the reasons why patients discontinued\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            therapy and to explore the outcomes of those patients who did discontinue treatment.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Retrospective evaluation of the case notes of a series of patients who had received intravesical\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            treatment at a large\n                            <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>\n                            teaching hospital.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>No antibiotic prophylaxis was given for the procedure.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Over a period of 7 years, 268 patients were initiated on intravesical\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            treatment for overactive bladder (\n                            <jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>\n                            ) at our institution, with 137 followed up for \u226536 months, with 80 patients having \u226560 months follow\u2010up after their first injection.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Almost two\u2010thirds of patients (61.3%) had discontinued intravesical\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            therapy at 36 months, with a 63.8% discontinuation rate at 60 months.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The main reasons for discontinuation were tolerability issues, mainly urinary tract infections and the need for clean intermittent self\u2010catheterisation. Primary and secondary losses of efficacy were of secondary importance.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Most of the patients that discontinued have remained under urology care and now receive alternative methods of treatment.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Intravesical\n                            <jats:styled-content style=\"fixed-case\">BT<\/jats:styled-content>\n                            therapy is an effective short\u2010term treatment for\n                            <jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>With time, two\u2010thirds of patients discontinued treatment usually because of the tolerability issues associated with treatment.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11282.x","type":"journal-article","created":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T08:39:21Z","timestamp":1338971961000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Long\u2010term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (\n                    <scp>OAB<\/scp>\n                    )"],"prefix":"10.1111","volume":"111","author":[{"given":"Amar","family":"Mohee","sequence":"first","affiliation":[{"name":"Department of Urology St James University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayisha","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Urology St James University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Urology St James University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Eardley","sequence":"additional","affiliation":[{"name":"Department of Urology St James University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42717-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.001"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.045765"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365590601068835"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.02.004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08402.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.01.117"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.130"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000177477.83991.88"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162035.73977.1c"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000132152.53532.5d"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.08.048"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.09.034"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.12.002"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.028"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04714.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.021"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.06.035"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.05.097"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21021"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-009-9600-7"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11282.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11282.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:21:36Z","timestamp":1761740496000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11282.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11282.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11282.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,6]]},"assertion":[{"value":"2012-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}